1. Lactobacillus gasseri SF1183 protects the intestinal epithelium and prevents colitis symptoms in vivo
- Author
-
Di Luccia, B, Mazzoli, A, DI LUCCIA AND MAZZOLI: FIRST COAUTHORSHIP, Cancelliere, R, Crescenzo, R, Ferrandino, I, Monaco, A, Bucci, A, Naclerio, G, Iossa, S, Ricca, E, Baccigalupi, L, Di Luccia, B, Mazzoli, A, DI LUCCIA AND MAZZOLI: FIRST, Coauthorship, Cancelliere, R, Crescenzo, R, Ferrandino, I, Monaco, A, Bucci, A, Naclerio, G, Iossa, S, Ricca, E, and Baccigalupi, L
- Subjects
0301 basic medicine ,Intestinal microbiota ,Medicine (miscellaneous) ,Biology ,Probiotic ,Lactobacillus gasseri ,law.invention ,Microbiology ,03 medical and health sciences ,0302 clinical medicine ,In vivo ,law ,medicine ,TX341-641 ,Secretion ,Colitis ,DSS ,Nutrition and Dietetics ,Nutrition. Foods and food supply ,DSS, Intestinal microbiota, Probiotic ,medicine.disease ,Antimicrobial ,biology.organism_classification ,Intestinal epithelium ,030104 developmental biology ,030211 gastroenterology & hepatology ,Bacteria ,Food Science - Abstract
Lactobacillus gasseri SF1183 belongs to a subpopulation of bacteria tightly associated to the human ileal epithelium. Cells of SF1183 survive and grow in simulated intestinal and gastric conditions, have a strong antimicrobial activity against Gram-positives and Gram-negatives and secrete molecule(s) sensed by human intestinal cells. We report that the oral administration of SF1183 cells had a protective effect in a murine model of DSS (Dextran-Sulfate-Sodium)-induced colitis. The analysis of the intestinal microbial composition indicated that several bacterial genera were differently represented in the intestine of DSS-treated animals. An overall similar alteration was observed in the microbiota of DSS-treated animals that received SF1183, suggesting that the beneficial role of the probiotic was not played through a reshuffling of the intestinal flora. Based on our in vivo data we propose the SF1183 strain of L. gasseri as a new anti-inflammatory probiotic, potentially useful as a therapeutic agent for the treatment of IBDs.
- Published
- 2018
- Full Text
- View/download PDF